GW 150013
Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 19 Nov 2001 Discontinued-II for Anxiety disorders in USA (Unknown route)
- 20 Mar 2001 Phase-II clinical trials for Anxiety disorders in USA (Unknown route)